{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:56:57Z","timestamp":1742392617266,"version":"3.37.3"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Juvenile scleroderma is a heterogeneous group of diseases associated with sclerotic skin lesions, grouped as juvenile systemic sclerosis and juvenile localized scleroderma. This study aims to measure the cytokine and chemokine levels involved in interferon (IFN) signalling in patients with juvenile scleroderma and determine their correlation with disease severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-nine juvenile localized scleroderma, five juvenile systemic sclerosis, and nine healthy controls were included in the study. Cytokines and chemokines involved in IFN gene signalling (IL-1, IL-6, IL-8, IP-10, MCP1, TNF-\u03b1, CXCL-11, IFN-\u03b1, IFN-\u03b2, IFN-\u03b3) and IFN-stimulated genes (ISGs), including IFI27, IFI44, ISIG15, IFIT1, OAS1, RSAD2, were measured by ELISA and RT-PCR method, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A significant increase in IFN-\u03b1, IFN-\u03b2, IFN-\u03b3, TNF-\u03b1, IL-1, IL-6 IL-8, IP-10, and MCP1 levels was observed in patients with juvenile systemic sclerosis compared with the healthy control group. Furthermore, IFN-\u03b1 and IP-10 were elevated in both juvenile localized scleroderma and juvenile systemic sclerosis compared to the healthy control group. IFN-\u03b3 and IFN-\u03b1 positively correlated with LoSAI and LoSDI levels, respectively. According to PGA-A analysis, IFN-\u03b2, IFN-\u03b3, TNF-\u03b1, IL-8, IP10, MCP1, and CXCL11 were significantly higher in active disease than in the inactive state in both groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The results suggest that IFN signalling may be impaired in patients with juvenile scleroderma. Significant changes were observed in cytokines and genes related to IFN signalling, which may have a crucial role in monitoring disease activity. In addition, we have gained important insights into the possibility of using IFN-\u03b1 and IFN-\u03b3 as biomarkers for monitoring juvenile scleroderma activity and damage.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae032","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T16:05:02Z","timestamp":1712419502000},"page":"1178-1184","source":"Crossref","is-referenced-by-count":2,"title":["Interferons dominate damage and activity in juvenile scleroderma"],"prefix":"10.1093","volume":"34","author":[{"given":"Hulya","family":"Kose","sequence":"first","affiliation":[{"name":"Department of Pediatric Immunology and Rheumatology, Bursa Uludag University Faculty of Medicine , Bursa,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdurrahman","family":"Simsek","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bursa Uludag University Faculty of Medicine , Bursa,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed Ali","family":"Kizmaz","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bursa Uludag University Faculty of Medicine , Bursa,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugce","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bursa Uludag University Faculty of Medicine , Bursa,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdi","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bursa Uludag University Faculty of Medicine , Bursa,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukru","family":"Cekic","sequence":"additional","affiliation":[{"name":"Department of Pediatric Immunology and Rheumatology, Bursa Uludag University Faculty of Medicine , Bursa,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferah","family":"Budak","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bursa Uludag University Faculty of Medicine , Bursa,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayriye","family":"Sar\u0131caoglu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bursa Uludag University Faculty of Medicine , Bursa,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-2581","authenticated-orcid":false,"given":"Sara Sebnem","family":"Kilic","sequence":"additional","affiliation":[{"name":"Department of Pediatric Immunology and Rheumatology, Bursa Uludag University Faculty of Medicine , Bursa,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"key":"2024110410405572400_R1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.berh.2018.02.004","article-title":"Scleroderma in children","volume":"31","author":"Zulian","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024110410405572400_R2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2018.12.018","article-title":"Type I interferon dysregulation in systemic sclerosis","volume":"132","author":"Skaug","year":"2020","journal-title":"Cytokine"},{"key":"2024110410405572400_R3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.pcl.2018.04.002","article-title":"Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis","volume":"65","author":"Li","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"2024110410405572400_R4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta","year":"2015","journal-title":"An Bras Dermatol"},{"key":"2024110410405572400_R5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jid.2018.09.025","article-title":"Identifying the signature immune phenotypes present in pediatric localized scleroderma","volume":"139","author":"Mirizio","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2024110410405572400_R6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005981","article-title":"Increased frequency and compromised function of T regulatory cells in systemic sclerosis (Juvenile systemic sclerosis) is related to a diminished CD69 and TGFbeta expression","volume":"4","author":"Radstake","year":"2009","journal-title":"PLoS One"},{"key":"2024110410405572400_R7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cyto.2014.11.026","article-title":"The role of type I interferons and other cytokines in dermatomyositis","volume":"73","author":"Arshanapalli","year":"2015","journal-title":"Cytokine"},{"key":"2024110410405572400_R8","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jid.2017.04.008","article-title":"Transcriptional and cytokine profiles identify CXCL9 as a biomarker of disease activity in Morphea","volume":"137","author":"O\u2019Brien","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2024110410405572400_R9","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101198","article-title":"SIGLEC-1 in systemic sclerosis: a useful biomarker for differential diagnosis","volume":"15","author":"H\u00f6ppner","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"article-title":"Human ELISA kit","year":"2023","author":"BTLAB, Shanghai Korain Biotech","key":"2024110410405572400_R10"},{"key":"2024110410405572400_R11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"2024110410405572400_R12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/ar290","article-title":"The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1\/Th2 paradigm in autoimmunity","volume":"3","author":"Theofilopoulos","year":"2001","journal-title":"Arthritis Res"},{"key":"2024110410405572400_R13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/BOR.0000000000000087","article-title":"Advances in understanding the role of type I interferons in systemic lupus erythematosus","volume":"26","author":"Crow","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"2024110410405572400_R14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1172\/JCI112956","article-title":"Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons","volume":"79","author":"Duncan","year":"1987","journal-title":"J Clin Invest"},{"key":"2024110410405572400_R15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/31.10.683","article-title":"Alpha interferon-2a (Roferon-A) in the treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis study group","volume":"31","author":"Stevens","year":"1992","journal-title":"Br J Rheumatol"},{"key":"2024110410405572400_R16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","article-title":"Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial","volume":"42","author":"Black","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2024110410405572400_R17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJM199104043241401","article-title":"Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy","volume":"4","author":"Castilla","year":"1991","journal-title":"N Engl J Med"},{"key":"2024110410405572400_R18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2169\/internalmedicine.46.6328","article-title":"Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C","volume":"46","author":"Tahara","year":"2007","journal-title":"Intern Med"},{"key":"2024110410405572400_R19","first-page":"625","article-title":"Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis","volume":"22","author":"Solans","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"2024110410405572400_R20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1046\/j.1365-2249.1999.00842.x","article-title":"Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud\u2019s phenomenon","volume":"116","author":"Molteni","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"2024110410405572400_R21","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024110410405572400_R22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"2024110410405572400_R23","first-page":"2","article-title":"Interleukin-6: a new therapeutic target in systemic sclerosis?","volume":"12","author":"O\u2019Reilly","year":"2013","journal-title":"Clin Transl Immunol"},{"key":"2024110410405572400_R24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.653950","article-title":"Interleukin-1 and systemic sclerosis: getting to the heart of cardiac involvement","volume":"12","author":"De Luca","year":"2021","journal-title":"Front Immunol"},{"key":"2024110410405572400_R25","first-page":"296","article-title":"Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts","volume":"25","author":"Kadono","year":"1998","journal-title":"J Rheumatol"},{"key":"2024110410405572400_R26","article-title":"Classical disease-specific autoantibodies in systemic sclerosis: clinical features, gene susceptibility, and disease stratification","volume":"7","author":"Yang","year":"2020","journal-title":"Front Med Lausanne"},{"key":"2024110410405572400_R27","doi-asserted-by":"crossref","DOI":"10.1186\/ar4378","article-title":"Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma","volume":"15","author":"Magee","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2024110410405572400_R28","first-page":"3193","article-title":"Biomarkers as an opportunity to stratify for outcome in systemic sclerosis","volume":"7","author":"Abignano","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"2024110410405572400_R29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.semarthrit.2015.06.006","article-title":"Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles","volume":"45","author":"Torok","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2024110410405572400_R30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024110410405572400_R31","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155633","article-title":"Abnormalities of the type I interferon signaling pathway in lupus autoimmunity","volume":"146","author":"Gallucci","year":"2021","journal-title":"Cytokine"},{"key":"2024110410405572400_R32","first-page":"1077","article-title":"Methods for type I interferon detection and their relevance for clinical utility and improved understanding of rheumatic diseases","volume":"37","author":"Lamot","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2024110410405572400_R33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1010702","article-title":"Protein prediction models support widespread post-transcriptional regulation of protein abundance by interacting partners","volume":"18","author":"Srivastava","year":"2022","journal-title":"PLoS Comput Biol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae032\/57677284\/roae032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/6\/1178\/60412112\/roae032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/34\/6\/1178\/60412112\/roae032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T10:41:11Z","timestamp":1730716871000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/34\/6\/1178\/7641821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,6]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae032","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"type":"print","value":"1439-7595"},{"type":"electronic","value":"1439-7609"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,4,6]]}}}